ArrayExpress Uploaderarrayexpress_sidhumanBV_ResponderBV_Non-responderBV_Non-responderBV_ResponderBV_ResponderBV_Responder, FL_Non_ResponderBV_Non-responderBV_Non-responderBV_Non-responderBV_ResponderBV_ResponderBV_Non-responderBV_Non-responderBV_Responder355104The patients who underwent surgery for primary lesions were examined. All patients had metastatic or recurrent CRC and received...E-GEOD-19862/profile/8773/arrayexpressuploader114cancercolorectal cancergenomelineDec.12, 2014FalseE-GEOD-19862_A-AFFY-44prediction-of-response-to-bevacizumabPrediction of response to bevacizumabSep.15, 2014The patients who underwent surgery for primary lesions were examined. All patients had metastatic or recurrent CRC and received bevacizumab therapy as first line or second line treatment. Responders and nonresponders were determined based on RECIST and confirmed by CT or MRI. Gene-expression profiles of primary CRC were determined using Human Genome GeneChip arrays U133. Colorectal cancer patients who had undergone surgical resection of colorectal cancer were studied. To identify molecular signatures to predict response to bevacizumab, gene expression profiles were compared between Reponder and Non-responder.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-19862http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-19862/samples/